| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.15 | 0.03 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.03 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.14 | 0.03 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.03 |
| mRNA | carboplatin:UNC0638 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.085 | 0.03 |